Respiratory CRO Services
Unlock success in your respiratory disease clinical trials
With rates of respiratory diseases on the rise, millions of patients globally rely on approved treatments and therapies to help them to breathe easier.
As disease prevalence increases, so too does the need to improve quality of life for patients. As a result, there has been an uptick in investment in respiratory disease drug development. Drug developers are on a mission to advance treatments for common respiratory diseases – including asthma and chronic obstructive pulmonary disease (COPD) – and rare respiratory diseases, like cystic fibrosis, idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
Developing therapies for respiratory diseases is complex and requires a focused clinical development strategy, supported by a seasoned contract research organization (CRO), to navigate the challenges specific to respiratory disease clinical trials across every phase.
By partnering with the PPD™ clinical research business of Thermo Fisher Scientific, you gain the benefits of:
- Subject matter expertise across a broad range of respiratory disease indications
- Resources to streamline the development process from Phase I through peri- and post-approval
- Access to diverse patients worldwide to ensure proper representation within your trial
- Seamless integration with PPD™ Laboratory teams, which provide data with immediacy, enabling you to make faster, more informed decisions during the trial
- Digital and decentralized solutions that increase patient engagement and retention and enhance the patient experience
- An expansive network of key sites and investigators
Keeping pace with evolving regulations is essential to success in respiratory disease clinical research. Our extensive regulatory experience is driven by teams of therapeutic experts who delve deep into guidance and bring their insights to your trial.
Our experience in respiratory clinical trials
Over the past five years, drug developers have turned to our clinical research team for our respiratory disease expertise, strong network of sites, and patient-centric solutions that advance drug development programs with speed, consistency and quality. In turn, we’ve contributed to the development of more than 20 marketed respiratory products.
Studies in respiratory indications
Respiratory patients
Global sites
Countries
Respiratory Rare Disease Trials – Optimizing Diversity and Decentralization
Respiratory disease research expertise
Understanding the nuances and complexities of respiratory research comes with experience – something our experts have in abundance.
Hear from our respiratory disease team about how they built their depth of experience across indications and how they use that knowledge to enable you to deliver life-changing therapies.
Respiratory clinical research experience indications
When you’re developing a respiratory disease treatment, you need a partner with the know how to move your program forward. Our respiratory team comprises experienced biostatisticians, clinical managers, clinical research associates (CRAs), data managers, medical staff and project managers who are well-versed in managing and monitoring the procedures associated with objectives and endpoints used in many respiratory protocols.
We have managed respiratory studies for various disease states, including:
- Acute and chronic sinusitis
- Allergic rhinitis (seasonal and perennial)
- Asthma (mild to severe)
- Chronic obstructive pulmonary disease (COPD)
- Cystic fibrosis
- Emphysema
- Idiopathic pulmonary fibrosis
- Malignant neoplasm of the trachea, bronchus and lung
- Other diseases of the lung and respiratory system
Laboratory services for respiratory disease clinical trials
Many respiratory disease trials require specialized inhalation testing capabilities to ensure effective drug delivery. Our comprehensive PPD Laboratory services include a GMP lab, which offers industry-leading support to respiratory trials of all size.